How low is too low? Experts debate blood pressure targets in post-SPRINT era

Following the landmark SPRINT trial, there is a growing body of evidence for reducing systolic blood pressure targets, resulting in the development of new US guidelines. However, this has led to many questions about the impact of such fundamental changes in blood pressure management, and whether they should be implemented in other constituencies. Two new studies published in the Canadian Journal of Cardiology assess the benefits and costs of incorporating these more aggressive goals into clinical practice. The Systolic Blood Pressure Intervention Trial (SPRINT) published in 2015 was a randomised, controlled, open-label trial conducted at 102 clinical sites in the US. It